Skip to content
Screener

Total Equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$439.74M-30.4%
Biogen logo
BiogenBIIB
$18.85B+6.9%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$1.31B+58.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$291M-293%
uniQure logo
uniQureQURE
$324.05M+8,195%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$218.05M-4.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.82B+150%
Enterprise value$1.61B+239%
P/S243.9×+154×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-207666
Line itemMarch 31,2026December 31,2025
Stockholders' equity
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 287,276,885 and 285,051,648 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively33
Additional paid-in capital964,666958,427
Accumulated other comprehensive income (loss)985(192)
Accumulated deficit(753,710)(711,300)
Total stockholders’ equity211,944246,938
Total liabilities and stockholders' equity$300,351$343,320

Item 1. Financial Statements.

FAQ

What is Taysha Gene Therapies, Inc.'s total equity?
Taysha Gene Therapies, Inc. (TSHA) reported total equity of $211.94M in Q1 2026.
How has Taysha Gene Therapies, Inc.'s total equity changed year-over-year?
Taysha Gene Therapies, Inc.'s total equity increased by 284.9% year-over-year, from $55.06M to $211.94M.
What is the long-term trend for Taysha Gene Therapies, Inc.'s total equity?
Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s total equity has grown at a -0.3% compound annual growth rate (CAGR), from $251.3M to $246.94M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Taysha Gene Therapies, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude